Revitalization Plan Will Benefit Biopharmaceutical And Chinese Medicine Industries
This article was originally published in PharmAsia News
Executive Summary
While the biomedical industry as a whole will receive significant policy and financial support from China's Twelfth Five-Year Plan, the biopharmaceutical and Chinese medicine industries will receive extra support from the biotech industry revitalization plan expected in August